Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosaroxin in High-Risk MDS
NCT01980056Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2013
- Primary completion
- Jan 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of vosaroxin in myelodysplastic syndrome (MDS), sponsored by Weill Cornell Medicine. Started Oct 2013; status: completed.
02
Drugs
vosaroxin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01980056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01980056.